Differential effects of iron deficiency on the expression of CD80 and CD86 co-stimulatory receptors in mitogen-treated and untreated murine spleen cells.
The interaction of CD28 and its ligands (CD80, CD86) on antigen presenting cells and that of TCR/CD3-MHC are required for T lymphocyte activation. To determine whether impaired lymphocyte proliferation associated with iron deficiency is due to reduced expression of these ligands, spleen cells obtained from eight to nine C57BL/6 mice/group of iron deficient (ID), iron replete (R), control (C), pair-fed (PF), and high iron (HI) mice were labeled with anti-CD80-fluorescein isothiocyante (FITC) and anti-CD86-FITC. Diets differed only in iron concentration: 5, 50, and 125 mg/kg for the ID, C, and HI, respectively. Mean levels of hemoglobin and liver iron stores of ID and R mice were less than 50% those of C mice (P < 0.005). In non-activated and concanavalin A-treated cultures, significant differences were observed among groups in the percentage of CD80 + cells: ID>R > C = PF = HI (P < 0.05). The same trend was observed for CD86 + cells (P > 0.05). Fluorescence intensity (FI) of either marker did not significantly change by iron status. In vitro iron chelation by deferoxamine (20, 200 microg/ml) for 1, 2, and 24 h increased FI of both markers on unactivated B and T cells (P < 0.05). However, it had no effect on FI of either marker of mitogen-treated cells presumably because the maximum levels are achieved by the mitogen. Lymphocyte proliferative responses to mitogens positively and significantly correlated with CD80 and CD86 FI (r = 0.41-0.59) but negatively correlated with the percentages of CD80 + cells (r = -0.48) (P < 0.05). Data suggest that impaired lymphocyte proliferation associated with iron deficiency is not due to reduced CD80 and CD86 expression.
Kuvibidila
Solo R
SR
Department of Pediatrics, Division of Hematology/Oncology, Section of Pulmonary Medicine, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, New Orleans, Louisiana 70112, USA. skuvib@lsuhsc.edu
Porretta
Connie
C
D018798:Anemia, Iron-Deficiency / Q000378:metabolism*; D000818:Animals; D015703:Antigens, CD / Q000032:analysis*; D018122:B7-1 Antigen / Q000032:analysis*; D051940:B7-2 Antigen; D015415:Biomarkers / Q000032:analysis; D002455:Cell Division / Q000187:drug effects; D003676:Deferoxamine / Q000494:pharmacology; D005260:Female; D005456:Fluorescent Dyes; D005786:Gene Expression Regulation / Q000187:drug effects*; D007501:Iron / Q000032:analysis; D007502:Iron Chelating Agents / Q000494:pharmacology; D000090463:Iron Deficiencies; D019266:Iron, Dietary / Q000008:administration & dosage / Q000494:pharmacology; D008099:Liver / Q000737:chemistry; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000032:analysis*; D051379:Mice; D008810:Mice, Inbred C57BL; D008934:Mitogens / Q000494:pharmacology*; D009929:Organ Size; D013154:Spleen / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*
D015703:Antigens, CD; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D015415:Biomarkers; C497965:Cd86 protein, mouse; D005456:Fluorescent Dyes; D007502:Iron Chelating Agents; D019266:Iron, Dietary; D008562:Membrane Glycoproteins; D008934:Mitogens; D007501:Iron; D003676:Deferoxamine